New prognostic markers in CLL.

New prognostic markers in CLL. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

New prognostic markers in CLL. Abstract Text:

Emili Montserrat,

The individual prognosis of patients with chronic lymphocytic leukemia (CLL) is extremely variable. Although clinical stages remain the basis for assessing prognosis in CLL, a number of biological markers, particularly serum markers, cytogenetic abnormalities, IgVH mutations, CD38 and ZAP-70 expression in leukemic cells offer important, independent prognostic information. Before being incorporated into daily practice, however, these markers require standardization and validation in large, prospective trials. Meanwhile, treatment of patients with CLL not included in clinical studies should be decided on the basis of classical NCI/CLL Working Group criteria. An important area of research in CLL prognostication is the identification of markers useful for predicting response to therapy and its duration. Among them, del(17p), reflecting P53 abnormalities, is particularly important. Also relevant is del(11q), which points to ATM defects. There is also some correlation between IgVH mutational status, ZAP-70 and CD38 expression and response to therapy and its duration, although these relationships need further investigation. Finally, there is increasing evidence that response to therapy, particularly in those cases in which minimal residual disease is eradicated, is associated with longer survival.

New prognostic markers in CLL. Publishing Authors By Initials

E Montserrat,

For similar diagnosis: prognosis: treatment outcome research abstracts see: diagnosis: prognosis: treatment outcome research

PUBMED ID PMID:

MEDLINE DATE:

New prognostic markers in CLL. Journal Published:

PUBLICATION TYPE: Review

Journal: Hematology / the Education Program of the American

VOLUME:

Page Numbers: 279-84

Journal Abbreviation:

ISSN: 1520-4391

DAY: 12

MONTH: 02

YEAR: 2006

New prognostic markers in CLL. Information

Number of References: 40

LANGUAGE: eng

NlmUniqueID: 100890099

New prognostic markers in CLL. Keywords Mesh Terms:

KEYWORDS: Treatment Outcome

MESH TERMS: genetics

Chemical & Substance for Abstract: New prognostic markers in CLL. Information

Substance Name: Biological Markers

Registry Number: 0

Grant and Affiliation Information for New prognostic markers in CLL.

AFFILIATION: Department of Hematology, Hospital Clínic, Villarroel 170, 08036 Barcelona, Spain. emontse@clinic.ub.es

Country: United States

AGENCY:

GRANT:

ACRONYM:

MEDLINETA: Hematology Am Soc Hematol Educ

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

New prognostic markers in CLL Related Publications

• Anemia associated with impaired erythropoietin secretion after allogeneic stem cell transplantation: incidence, risk factors, and response to treatment.
• Autologous stem cell transplantation for patients with active Hodgkin's lymphoma: long-term outcome of 61 patients from a single institution.
• Central nervous system involvement in mantle cell lymphoma.
• Chronic lymphocytic leukemia: case-based session.
• Clinical implications of ZAP-70 expressionin chronic lymphocytic leukemia.
• Fludarabine, cyclophosphamide, and mitoxantrone as initial therapy of chronic lymphocytic leukemia: high response rate and disease eradication.
• Further progress in CLL therapy.
• Kinetics of recovery of dendritic cell subsets after reduced-intensity conditioning allogeneic stem cell transplantation and clinical outcome.
• Management of sleep apnea: concordance between nonreference and reference centers.
• New prognostic markers in CLL.
• New prognostic markers in chronic lymphocytic leukemia.
• Potential dermal exposure to deltamethrin and risk assessment for manual sprayers: Influence of crop type.
• [Autologous haematopoietic stem cell transplantation in POEMS syndrome: results in 4 cases.]
• [Clinical forms of the sympathetic temporomandibular syndrome of Costen-Abelló.]
• [Not Available.]
• [Not Available.]